...
acrs-img

Aclaris Therapeutics Inc, Common Stock

ACRS

NSQ

$3.27

-$0.27

(-7.63%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$279.30M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
682.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.12
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.8 L
$5.17 H
$3.27

About Aclaris Therapeutics Inc, Common Stock

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameACRSSectorS&P500
1-Week Return-14.17%-2.82%0.15%
1-Month Return27.73%-4.22%1.78%
3-Month Return179.49%-9.52%8.7%
6-Month Return184.35%-3.45%12.24%
1-Year Return223.76%5.62%30.9%
3-Year Return-76.69%3.8%30.19%
5-Year Return89.02%39.68%91.72%
10-Year Return-70.41%105.02%203.2%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue4.23M6.48M6.76M29.75M31.25M[{"date":"2019-12-31","value":13.53,"profit":true},{"date":"2020-12-31","value":20.74,"profit":true},{"date":"2021-12-31","value":21.64,"profit":true},{"date":"2022-12-31","value":95.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue4.05M5.13M4.71M11.96M18.08M[{"date":"2019-12-31","value":22.43,"profit":true},{"date":"2020-12-31","value":28.39,"profit":true},{"date":"2021-12-31","value":26.07,"profit":true},{"date":"2022-12-31","value":66.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit172.00K1.35M2.05M17.79M13.17M[{"date":"2019-12-31","value":0.97,"profit":true},{"date":"2020-12-31","value":7.58,"profit":true},{"date":"2021-12-31","value":11.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.01,"profit":true}]
Gross Margin4.07%20.81%30.29%59.80%42.14%[{"date":"2019-12-31","value":6.8,"profit":true},{"date":"2020-12-31","value":34.8,"profit":true},{"date":"2021-12-31","value":50.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.47,"profit":true}]
Operating Expenses92.73M52.26M67.43M102.95M130.80M[{"date":"2019-12-31","value":70.89,"profit":true},{"date":"2020-12-31","value":39.96,"profit":true},{"date":"2021-12-31","value":51.56,"profit":true},{"date":"2022-12-31","value":78.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(111.06M)(50.91M)(65.38M)(85.15M)(97.36M)[{"date":"2019-12-31","value":-11105800000,"profit":false},{"date":"2020-12-31","value":-5091200000,"profit":false},{"date":"2021-12-31","value":-6538400000,"profit":false},{"date":"2022-12-31","value":-8515400000,"profit":false},{"date":"2023-12-31","value":-9735700000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(113.54M)(51.34M)(90.86M)(86.91M)(88.85M)[{"date":"2019-12-31","value":-11354200000,"profit":false},{"date":"2020-12-31","value":-5133600000,"profit":false},{"date":"2021-12-31","value":-9086500000,"profit":false},{"date":"2022-12-31","value":-8690800000,"profit":false},{"date":"2023-12-31","value":-8884800000,"profit":false}]
Income Taxes29.31M(182.00K)23.42M1.75M(367.00K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.62,"profit":false},{"date":"2021-12-31","value":79.9,"profit":true},{"date":"2022-12-31","value":5.98,"profit":true},{"date":"2023-12-31","value":-1.25,"profit":false}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(113.54M)(51.15M)(90.86M)(86.91M)(88.48M)[{"date":"2019-12-31","value":-11354200000,"profit":false},{"date":"2020-12-31","value":-5115400000,"profit":false},{"date":"2021-12-31","value":-9086500000,"profit":false},{"date":"2022-12-31","value":-8690800000,"profit":false},{"date":"2023-12-31","value":-8848100000,"profit":false}]
Income From Discontinued Operations(47.81M)139.00K---[{"date":"2019-12-31","value":-34397.12,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(142.85M)(51.15M)(114.28M)(88.66M)(88.48M)[{"date":"2019-12-31","value":-14285000000,"profit":false},{"date":"2020-12-31","value":-5115400000,"profit":false},{"date":"2021-12-31","value":-11428100000,"profit":false},{"date":"2022-12-31","value":-8866200000,"profit":false},{"date":"2023-12-31","value":-8848100000,"profit":false}]
EPS (Diluted)(3.46)(1.20)(1.63)(1.33)(1.25)[{"date":"2019-12-31","value":-346,"profit":false},{"date":"2020-12-31","value":-120,"profit":false},{"date":"2021-12-31","value":-163,"profit":false},{"date":"2022-12-31","value":-133,"profit":false},{"date":"2023-12-31","value":-125,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ACRS
Cash Ratio 6.79
Current Ratio 7.03

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ACRS
ROA (LTM) -19.39%
ROE (LTM) -25.83%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ACRS
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ACRS
Trailing PE NM
Forward PE NM
P/S (TTM) 9.34
P/B 1.79
Price/FCF 11
EV/R 4.24
EV/Ebitda 0.28
PEG NM

FAQs

What is Aclaris Therapeutics Inc share price today?

Aclaris Therapeutics Inc (ACRS) share price today is $3.27

Can Indians buy Aclaris Therapeutics Inc shares?

Yes, Indians can buy shares of Aclaris Therapeutics Inc (ACRS) on Vested. To buy Aclaris Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACRS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aclaris Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Aclaris Therapeutics Inc (ACRS) via the Vested app. You can start investing in Aclaris Therapeutics Inc (ACRS) with a minimum investment of $1.

How to invest in Aclaris Therapeutics Inc shares from India?

You can invest in shares of Aclaris Therapeutics Inc (ACRS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ACRS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aclaris Therapeutics Inc shares
What is Aclaris Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Aclaris Therapeutics Inc (ACRS) is $5.17. The 52-week low price of Aclaris Therapeutics Inc (ACRS) is $0.8.

What is Aclaris Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Aclaris Therapeutics Inc (ACRS) is

What is Aclaris Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aclaris Therapeutics Inc (ACRS) is 1.79

What is Aclaris Therapeutics Inc dividend yield?

The dividend yield of Aclaris Therapeutics Inc (ACRS) is 0.00%

What is the Market Cap of Aclaris Therapeutics Inc?

The market capitalization of Aclaris Therapeutics Inc (ACRS) is $279.30M

What is Aclaris Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Aclaris Therapeutics Inc is ACRS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top